Publication: Patient-ready syringes containing 25 mg/mL methotrexate can be kept at temperature ranging from 4 °C to 37 °C for up to 12 weeks for use in psoriatic and rheumatologic conditions
Issued Date
2020-01-01
Resource Type
ISSN
14711753
09546634
09546634
Other identifier(s)
2-s2.0-85088875614
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Dermatological Treatment. (2020)
Suggested Citation
Leena Chularojanamontri, Chanisada Wongpraparut, Narumol Silpa-Archa, Chayada Chaiyabutr, Chutipon Pruksaeakanan, Anchalika Klinniyom, Sarawut Junnu, Chatchawan Srisawat Patient-ready syringes containing 25 mg/mL methotrexate can be kept at temperature ranging from 4 °C to 37 °C for up to 12 weeks for use in psoriatic and rheumatologic conditions. Journal of Dermatological Treatment. (2020). doi:10.1080/09546634.2020.1800570 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/58224
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Patient-ready syringes containing 25 mg/mL methotrexate can be kept at temperature ranging from 4 °C to 37 °C for up to 12 weeks for use in psoriatic and rheumatologic conditions
Other Contributor(s)
Abstract
© 2020 Taylor & Francis Group, LLC. Background: Methotrexate (MTX) is a mainstay drug in the treatment of psoriatic and rheumatologic conditions. Subcutaneous MTX has become a feasible treatment alternative with the development of prefilled syringes or autoinjectors containing MTX solution that can be self-administered by the patient at home. However, MTX prefilled auto-injector pens are still not available in some countries. Objective: This study aimed to investigate the stability and sterility of 25 mg/mL MTX solution in a disposable plastic syringe over a 12-week period under light protection at temperatures of 4 °C, 25 °C, and 37 °C. Methods: This study was conducted during November 2019 to February 2020 at the Faculty of Medicine Siriraj Hospital, Mahidol University. Stability was evaluated using ultra-high-performance liquid chromatography technique, and sterility was assessed by cultures for bacterial and fungal contamination. Results: Our results revealed that patient-ready syringes containing 25 mg/mL MTX solution can be prepared in advance and kept for up to 12 weeks under light protection, and they can be kept at temperatures ranging from 4 to 37 °C. Conclusion: This system for delivering MTX to patients that are refractory to or intolerant of oral MTX via a self-administered pre-filled syringe is both efficient and easy to implement in care settings where commercially alternatives are not yet available.